|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
ATE240740T1
(de)
|
1991-03-15 |
2003-06-15 |
Amgen Inc |
Pegylation von polypeptiden
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
FI941572A7
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
|
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
HUP0301208A2
(hu)
|
1999-02-12 |
2003-08-28 |
Genetics Institute, Llc |
B7-molekulákkal reagáló humanizált immunglobulin és az ezekkel végzett kezelési eljárások
|
|
EP1212422B1
(en)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
JP2003520828A
(ja)
|
2000-01-27 |
2003-07-08 |
ジェネティクス インスティテュート，エルエルシー |
Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
|
|
EP1354600A1
(en)
|
2002-04-19 |
2003-10-22 |
Affimed Therapeutics AG |
Antibody combination useful for tumor therapy
|
|
HRP20120845T1
(hr)
|
2003-07-02 |
2012-11-30 |
Innate Pharma |
Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
ATE475669T1
(de)
|
2004-06-29 |
2010-08-15 |
Immunocore Ltd |
Einen modifizierten t-zellen-rezeptor exprimierende zellen
|
|
EP1699826B1
(en)
|
2005-01-05 |
2009-03-11 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
WO2008103849A2
(en)
|
2007-02-21 |
2008-08-28 |
The Regents Of The University Of California |
Methods and compounds for lymphoma cell detection and isolation
|
|
EP1829895A1
(en)
|
2006-03-03 |
2007-09-05 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
|
|
EP2097447A4
(en)
|
2006-11-15 |
2010-12-29 |
Medarex Inc |
HUMAN MONOCLONAL ANTIBODIES AGAINST BTLA AND METHODS OF USE
|
|
WO2008076868A2
(en)
|
2006-12-18 |
2008-06-26 |
Abbott Laboratories |
Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)
|
|
US8163279B2
(en)
|
2007-04-13 |
2012-04-24 |
Stemline Therapeutics, Inc. |
IL3Rα antibody conjugates and uses thereof
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
EP2316491B1
(en)
|
2008-07-18 |
2016-10-12 |
National University Corporation Nagoya University |
Cell proliferation inhibitor
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
EP2367553B1
(en)
|
2008-12-05 |
2017-05-03 |
Novo Nordisk A/S |
Combination therapy to enhance nk cell mediated cytotoxicity
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
CA2756244A1
(en)
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
|
SG175077A1
(en)
|
2009-04-07 |
2011-11-28 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
|
CA2759733C
(en)
|
2009-04-23 |
2019-09-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-human ror1 antibodies
|
|
PE20120540A1
(es)
|
2009-05-27 |
2012-05-09 |
Hoffmann La Roche |
Anticuerpos triespecificos o tetraespecificos
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
US8703132B2
(en)
|
2009-06-18 |
2014-04-22 |
Hoffmann-La Roche, Inc. |
Bispecific, tetravalent antigen binding proteins
|
|
WO2011054007A1
(en)
|
2009-11-02 |
2011-05-05 |
Oxford Biotherapeutics Ltd. |
Ror1 as therapeutic and diagnostic target
|
|
US9150647B2
(en)
|
2009-12-18 |
2015-10-06 |
Kancera Ab |
Biological inhibitors of ROR1 capable of inducing cell death
|
|
US20110165161A1
(en)
*
|
2009-12-23 |
2011-07-07 |
Shih-Yao Lin |
Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
|
|
KR20130036192A
(ko)
|
2010-02-11 |
2013-04-11 |
알렉시온 파마슈티칼스, 인코포레이티드 |
항-ｃｄ200 항체들을 이용한 치료 및 진단 방법
|
|
US9242014B2
(en)
|
2010-06-15 |
2016-01-26 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
|
|
EP3828205A1
(en)
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1 antibodies
|
|
CN103459425B
(zh)
*
|
2010-10-27 |
2015-11-25 |
安进研发（慕尼黑）股份有限公司 |
用于治疗dlbcl的组合物
|
|
ES2657970T3
(es)
*
|
2010-12-01 |
2018-03-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticuerpos contra ROR1 de conejo/ser humano quiméricos
|
|
GB201020995D0
(en)
|
2010-12-10 |
2011-01-26 |
Bioinvent Int Ab |
Biological materials and uses thereof
|
|
EP3604339B1
(en)
|
2011-01-14 |
2021-03-10 |
The Regents Of The University Of California |
Therapeutic antibodies against ror-1 protein and methods for use of same
|
|
US20140242081A1
(en)
*
|
2011-07-18 |
2014-08-28 |
Micromet Ag |
Dosing regimens for treatment of cea-expressing cancers
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
BR122020002986A8
(pt)
*
|
2012-08-20 |
2023-04-18 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Método e composições para imunoterapia celular
|
|
US20140308285A1
(en)
|
2013-03-15 |
2014-10-16 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
|
US20140302037A1
(en)
*
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
EP2789630A1
(en)
*
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
|
WO2015097536A2
(en)
|
2013-12-24 |
2015-07-02 |
Janssen Pharmaceutical Nv |
Anti-vista antibodies and fragments
|
|
HUE045065T2
(hu)
|
2014-01-31 |
2019-12-30 |
Novartis Ag |
TIM-3 antitest molekulák és felhasználásaik
|
|
EA035419B9
(ru)
*
|
2014-05-29 |
2020-08-07 |
Мэкроудженикс, Инк. |
Триспецифичные связывающие молекулы и способы их применения
|
|
PE20171324A1
(es)
*
|
2014-11-26 |
2017-09-11 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
|